Steven Shak Sells 1,500 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 1,500 shares of Genomic Health stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $78.18, for a total value of $117,270.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Shak also recently made the following trade(s):

  • On Monday, September 10th, Steven Shak sold 5,500 shares of Genomic Health stock. The shares were sold at an average price of $63.05, for a total value of $346,775.00.

GHDX opened at $72.90 on Friday. Genomic Health, Inc. has a twelve month low of $26.54 and a twelve month high of $92.18. The company has a market capitalization of $2.73 billion, a P/E ratio of 92.07 and a beta of 0.40.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.28. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The firm had revenue of $101.30 million during the quarter, compared to analyst estimates of $94.27 million. During the same period in the previous year, the company earned ($0.06) EPS. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. Analysts predict that Genomic Health, Inc. will post 1.06 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Genomic Health by 18.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after purchasing an additional 337,664 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Genomic Health by 1.7% during the third quarter. BlackRock Inc. now owns 2,037,436 shares of the medical research company’s stock worth $143,070,000 after buying an additional 34,464 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Genomic Health by 26.9% during the third quarter. Renaissance Technologies LLC now owns 1,783,100 shares of the medical research company’s stock worth $125,209,000 after buying an additional 378,176 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Genomic Health by 114.0% during the second quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock worth $72,891,000 after buying an additional 770,413 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Genomic Health by 112.8% during the third quarter. Acadian Asset Management LLC now owns 525,376 shares of the medical research company’s stock worth $36,891,000 after buying an additional 278,516 shares during the last quarter. Hedge funds and other institutional investors own 89.21% of the company’s stock.

Several brokerages have recently issued reports on GHDX. BidaskClub lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Raymond James began coverage on Genomic Health in a report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Zacks Investment Research lowered Genomic Health from a “buy” rating to a “hold” rating in a report on Thursday, August 30th. Finally, Canaccord Genuity restated a “buy” rating and issued a $82.00 target price (up from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $48.33.

ILLEGAL ACTIVITY WARNING: “Steven Shak Sells 1,500 Shares of Genomic Health, Inc. (GHDX) Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/08/steven-shak-sells-1500-shares-of-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Article: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply